Although these studies demonstrated the elimination of malignan T cells from immunodeficient mice, they do not reflect the clinical situation of the immunocompetent patient who is tolerant to CD19 self-antigen and experienced a long adaptation to the growing tumor cell mass. The gene discussed is CD19; the disease is neoplasm.